CBR1 Recombinant Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with CBR1 monoclonal antibody, unconjugated (bsm-61367R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with CBR1 monoclonal antibody, unconjugated (bsm-61367R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
IHC-P
IHC-F
IF
ICC/IF

Reactivity

Human

Overview
Catalog #	bsm-61367r-TR
Product Name	CBR1 Recombinant Antibody
Applications	WB, IHC-P, IHC-F, IF, ICC/IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human CBR1
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	873
Swiss Prot	P16152
Subcellular location	Cytoplasm
Synonyms	15 hydroxyprostaglandin dehydrogenase [NADP+]; Carbonyl reductase [NADPH] 1; CBR1; CRN; NADPH dependent carbonyl reductase 1; Prostaglandin 9 ketoreductase; SDR21C1.
Background	NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IF
ICC/IF	1:50-100